COMMUNIQUÉS West-GlobeNewswire

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
27/10/2025
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, [...]
Cannabix Technologies Granted Patent from USPTO for Contactless Breath Analysis
27/10/2025
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to report that the United States Patent and [...]
Philips introduces industry-first cath lab integration that automatically synchronizes pre-operative CT with C-arm movement, paving the way for CT-guided PCI
27/10/2025
October 27, 2025 New integration of Philips Advanced Visualization Workspace* with the Azurion image-guided therapy platform automatically synchronizes CT images with C-arm movement, supporting workflow efficiency and [...]
Omada Health Welcomes Thomas Tsang, MD, MPH as Chief Medical Officer
27/10/2025
Healthcare veteran brings expertise in clinical care delivery, digital health, and policy to virtual-first healthcare provider SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual [...]
Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth
27/10/2025
DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today [...]
Curia investit 4 millions de dollars pour renforcer la fabrication stérile de substances actives (API)
27/10/2025
ALBANY, New York, 27 oct. 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui l’achèvement d’un [...]
Curia Invests $4 Million to Enhance Sterile API Manufacturing
27/10/2025
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its [...]
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
27/10/2025
Orchestra BioMed’s Virtue ® Sirolimus AngioInfusion TM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus (“ [...]
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
27/10/2025
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) [...]
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
27/10/2025
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Prenetics Announces $48.0 Million Equity Offering to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
27/10/2025
CHARLOTTE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“ Prenetics ” or the “ Company ”), a leading health sciences company, today announced the successful pricing of a best efforts [...]
A New Era for Dermatology PAs and NPs Begins with PANP360
27/10/2025
The one-of-a-kind platform unites peer connection, clinical learning, and purpose under one home Plano, Texas, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Dermsquared is proud to announce the launch of PANP360 , a reimagined hub [...]
Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
27/10/2025
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of new data at the AACR- [...]
NHS-licensed healthcare platform Evaro partners with period tracking app Clue in UK-first integration
27/10/2025
Partnership bridges the gap between period tracking and contraception access as nearly half of UK women face barriers to contraception care LONDON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Evaro, the NHS-licensed embedded [...]
Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis
27/10/2025
Clinical and Pharmacology Data Presented at ACR Convergence 2025 In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients with [...]
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
27/10/2025
The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation Targeted Glue™ medicinal chemistry technology Amphista’s scientists prospectively [...]
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
27/10/2025
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading [...]
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
27/10/2025
WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
27/10/2025
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in [...]

Pages